DeepMed Research

MedImmune LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1987-01-01

Employees: 5K

Market Cap: -

Website: http://medimmune.com

Clinical Trials

A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults

Phase 4

Completed

Conditions: Healthy

Interventions: Biological: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]
Other: Placebo

First Posted Date: 2009-07-24

Last Posted Date: 2011-09-12

Lead Sponsor: MedImmune LLC

Target Recruit Count: 300

Registration Number: NCT00945893

Locations: 🇺🇸
Clinical Research Associates, Inc., Nashville, Tennessee, United States
🇺🇸
Covance Daytona Beach, Daytona Beach, Florida, United States
🇺🇸
Center for Pharmaceutical Research, Kansas City, Missouri, United States

and more 2 locations

A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age

Phase 4

Completed

Conditions: Influenza

Interventions: Biological: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]
Biological: Placebo

First Posted Date: 2009-07-24

Last Posted Date: 2011-08-11

Lead Sponsor: MedImmune LLC

Target Recruit Count: 326

Registration Number: NCT00946101

Locations: 🇺🇸
Primary Physicians Research, Inc., Pittsburgh, Pennsylvania, United States
🇺🇸
Sundance Clinical Research, St. Louis, Missouri, United States
🇺🇸
Clinical Research Center of Nevada, Henderson, Nevada, United States

and more 11 locations

A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

Phase 1

Completed

Conditions: Scleroderma

Interventions: Drug: MEDI-546

First Posted Date: 2009-06-30

Last Posted Date: 2012-05-08

Lead Sponsor: MedImmune LLC

Target Recruit Count: 34

Registration Number: NCT00930683

Locations: 🇺🇸
Boston University, Boston, Massachusetts, United States
🇺🇸
University of Utah Medical Center, Salt Lake City, Utah, United States
🇺🇸
Research Site, Seattle, Washington, United States

and more 1 locations

Respiratory Events Among Premature Infants

Completed

Conditions: Respiratory Syncytial Virus

First Posted Date: 2009-04-28

Last Posted Date: 2009-08-07

Lead Sponsor: MedImmune LLC

Target Recruit Count: 50

Registration Number: NCT00889070

Locations: 🇺🇸
Suny Upstate Medical University, Syracuse, New York, United States
🇺🇸
Children's Primary Care Medical Group, Inc., San Diego, California, United States
🇺🇸
Senders Pediatrics, Cleveland, Ohio, United States

and more 2 locations

Study to Evaluate the Safety and Efficacy of CAT-354

Phase 2

Completed

Conditions: Asthma

Interventions: Biological: CAT-354 150 mg
Other: Placebo
Biological: CAT-354 300 mg
Biological: CAT-354 600 mg

First Posted Date: 2009-04-02

Last Posted Date: 2017-03-24

Lead Sponsor: MedImmune LLC

Target Recruit Count: 357

Registration Number: NCT00873860

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

A Prospective Study to Evaluate the Safety of a New Monovalent Intranasal Influenza Vaccine

Phase 4

Completed

Conditions: Healthy

Interventions: Biological: Monovalent influenza virus vaccine
Biological: Placebo

First Posted Date: 2009-04-02

Last Posted Date: 2011-07-14

Lead Sponsor: MedImmune LLC

Target Recruit Count: 300

Registration Number: NCT00873912

Locations: 🇺🇸
Covance CRU, Inc, Austin, Texas, United States
🇺🇸
Covance CRU, Inc., Daytona Beach, Florida, United States

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age

Phase 2

Completed

Conditions: Healthy or Stable Underlying Chronic Medical Condition

Interventions: Biological: Q/LAIV (MEDI3250)
Biological: FluMist/B/Yamagata
Biological: FluMist/B/Victoria

First Posted Date: 2009-03-11

Last Posted Date: 2011-12-05

Lead Sponsor: MedImmune LLC

Target Recruit Count: 1800

Registration Number: NCT00860067

Locations: 🇺🇸
University Clinical Research, Inc, Pembroke Pines, Florida, United States
🇺🇸
Advanced Clinical Research, West Jordan, Utah, United States
🇺🇸
Rochester Clinical Research, Inc., Rochester, New York, United States

and more 12 locations

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: MEDI-575

First Posted Date: 2009-01-01

Last Posted Date: 2018-06-26

Lead Sponsor: MedImmune LLC

Target Recruit Count: 49

Registration Number: NCT00816400

Locations: 🇺🇸
Research Site, Norfolk, Virginia, United States

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: MEDI-573

First Posted Date: 2009-01-01

Last Posted Date: 2019-03-04

Lead Sponsor: MedImmune LLC

Target Recruit Count: 43

Registration Number: NCT00816361

Locations: 🇺🇸
Research Site, Philadelphia, Pennsylvania, United States

Study of MEDI 507 in the Treatment of Pediatric Patients

Phase 1

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: MEDI-507

First Posted Date: 2008-12-23

Last Posted Date: 2008-12-23

Lead Sponsor: MedImmune LLC

Target Recruit Count: 10

Registration Number: NCT00813618

Locations: 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Children's Hospital, Birmingham, Alabama, United States
🇺🇸
Hackensack U. Medical Center, Hackensack, New Jersey, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy